New prostate cancer drug trial for chinese men
NCT ID NCT07339267
First seen Jan 22, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This early-stage study tests a new drug called ASP5541 in about 12 Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to see if the drug is safe and how it is processed by the body. Men will keep receiving the treatment until their cancer worsens or their doctor decides to stop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital
RECRUITINGBeijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.